0.24
+0.035(+17.07%)
Currency In CAD
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
May 27, 2008
| Name | Title | Pay | Year Born |
| Mr. Dwight Gorham | Chief Executive Officer & Director | 316,887 | 1958 |
| Mr. Tommy Kenny J.D., L.L.B., M.Sc. | Senior Vice President & General Counsel | 209,754 | 1987 |
| Ms. Nadine Paiement M.Sc. | Vice-Chair of Scientific Advisory Board and Vice President of Research & Development - IntelGenx Corp | 215,087 | 1977 |
| Mr. André Godin C.A., CPA, CA, CPA | President & Chief Financial Officer | 359,578 | 1964 |
| Ms. Ingrid Zerbe | Corporate Secretary | 0 | 1954 |
| Zenoz Nina Pourhassan | Vice President of Quality Operations of Subsidiary | 0 | N/A |
| Ms. Karen Kalayajian CPA | Vice President of Finance & Administration | 0 | 1980 |
| Stephen Kilmer | Investor Relations Officer | 0 | N/A |
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.